Clinical Trial Detail

NCT ID NCT02919969
Title Pembrolizumab in Refractory Metastatic Anal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

anus cancer

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.